Company profile
NKARTA, INC.
NASDAQ:NKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BELACABNAGENE FRANLEUCEL | phase1_2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06557265 | phase1_2 | recruiting | 2024-06-13 | 2027-04-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) |
| NCT06733935 | phase1_2 | recruiting | 2024-11-04 | 2028-10-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) |
| NCT05020678 | phase1 | active_not_recruiting | 2021-08-20 | 2025-03-31 | Nkarta, Inc. | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
| NCT04623944 | phase1 | active_not_recruiting | 2020-09-21 | 2024-10-02 | Nkarta, Inc. | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS |
FDA applications (0)
No records yet.